ACARIZAX Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma. A randomized clinical trial
Virchow et al, JAMA 2016; 315 (16): 1715-1725
ACARIZAX Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet
Demoly et al, J Allergy Clin Immunol 2016; 137 (2): 444-451
ACARIZAX Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber
Nolte et al, J Allergy Clin Immunol 2015; 135(6):1494-1501
ACARIZAX Standardized quality (SQ) house dust mite sublingual immmunotherapy tablet
Mosbech et al, J Allergy Clin Immunol 2014 Sep; 134 (3): 568-575.e7
ALK SQ A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients
Wang et al, Allergy 2006; 61: 191-197
ALK SQ A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ
Dolz et al, Allergy 1996; 51: 489-500
GRAZAX Tolerability of the SQ‑standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non‑interventional observational study
Reiber et al, Clin Transl Allergy 2016;6:9 DOI: 10.1186/s13601-016-0097-8
GRAZAX Efficacy and safety of grass sublingual immunotherapy tablet
Maloney et al, Ann Allergy Asthma Immunol 2014; 112: 146-153
GRAZAX Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults
Nelson et al, J Allergy Clin Immunol 2011; 127: 72-80
GRAZAX Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual Immunotherapy
Bufe et al, J Allergy Clin Immunol 2009; 123: 167-173
GRAZAX Safey of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children
Ibanez et al, Pediatr Allergy Immunol 2007; 18: 516-522
